

SGN-35T

An investigational CD30directed, next-generation antibody-drug conjugate with novel tripeptide linker

Anti-CD30 monoclonal antibody


Chimeric IgG1 antibody that binds to human CD30

MMAE

Microtubule-disrupting agent

Protease-cleavable tripeptide linker

Designed to improve preferential cleavage in target cells



Target: CD30

• CD30 is expressed in many B- and T-cell lymphomas, while having

Proposed Mechanism of Action^{2-3,a}

- Direct cytotoxicity
- CD30+ Treg depletion

limited expression in normal tissue¹

- Bystander effect
- Immunogenic cell death

CD30: cluster of differentiation 30; **IgG1**: immunoglobulin G1; **MMAE**: monomethyl auristatin E ^aBased on preclinical data

1. Wahl AF. Cancer Res. 2002: 3736-42. 2. Hamblett K. EORTC 2023: Poster C132. 3. O'Connor BP. SITC 2023: Poster 1155.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.





Proposed Mechanism of Action^{1,2,a}



Binds to CD30



Complex internalization and MMAE release



CD30

Cell cycle arrest and apoptotic cell death

Tripeptide linker designed to improve preferential cleavage in target cells

MMAE

Endoplasmic reticulum stress

Bystander effect

CD30+ Treg

depletion

Immunogenic cell death

Direct cytotoxicity

Lysosome



CD30: cluster of differentiation 30; **MMAE**: monomethyl auristatin E; **Treg**: regulatory T cell

^aBased on preclinical data

1. Hamblett K. EORTC 2023: Poster C132. 2. O'Connor BP. SITC 2023: Poster 1155.

Clinical Trials		Phase 1	Phase 2	Phase 3
NOT YET RECRUITING	SGN35T-001: Lymphomas (NCT06120504) SGN-35T			

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.



The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.

© 2023 Seagen Inc., Bothell, WA 98021 Printed in the USA USM/35T/2023/0002 For more information, contact us at:

+1-855-4SEAGEN (+1-855-473-2436) medinfo@seagen.com / medinfoEU@seagen.com www.seagenmedinfo.com